Routine compliance certificate filed with NSE for Q2 FY26

Compliance View source PDF Explain this filing

ZENITHDRUG · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.4%Reaction day

₹40.15

prior close

—

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.8%-1.2% vs market

On the reaction day the stock moved 1.2 pts less than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs market

Reaction day

-0.4+0.8-1.2

Next day

-3.4+1.0-4.4

-1.9+1.7-3.6

-0.4+0.1-0.4

+3.1+0.8+2.3

-2.9-0.9-2.0

-4.9-4.5-0.4

15d

———

UpDownMarket · Nifty Microcap 250Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Zenith Drugs has submitted to NSE a compliance certificate under SEBI Regulation 74(5) for the quarter ended September 30, 2026. The certificate was issued by Bigshare Services, the company's Registrar and Transfer Agent. It confirms that the regulation is not applicable to the company because all its shares are held in demat form, and no requests for rematerialization were received during the quarter. This is a standard quarterly procedural filing with no business or financial activity.

Likely market impact

No material impact on shareholders. This is a routine regulatory filing with no effect on stock price or operations.